title: Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
abstract: The influence of cytochrome P450 2D6 (CYP2D6) genetic variability was examined in psychiatric inpatients by evaluating adverse drug events (ADEs), hospital stays, and total costs over a 1-year period in an extension of a previously published brief report. One hundred consecutive psychiatric patients from Eastern State Hospital in Lexington, Kentucky, were genotyped for CYP2D6 expression. ADEs were evaluated by a neurologic rating scale, modified Udvalg for Kliniske Undersogelser Side Effect Rating Scale, or chart review. Information on total hospitalization days and total costs were gathered for a 1-year period. Forty-five percent of the patients received medications that were primarily dependent on the CYP2D6 enzyme for their elimination. When the analysis was restricted to just those patients in each group receiving medication heavily dependent on the CYP2D6 enzyme, the following were observed: (1) a trend toward greater numbers of ADEs from medications as one moved from the group with ultrarapid CYP2D6 activity (UM) to the group with absent CYP2D6 activity (PM); (2) the cost of treating patients with extremes in CYP2D6 activity (UM and PM) was on average $4,000 to $6,000 per year greater than the cost of treating patients in the efficient metabolizer (EM) and intermediate metabolizer (IM) groups; and (3) total duration of hospital stay was more pronounced for those in CYP2D6 PM group. Variance of hospital stays and costs calculated from these preliminary data suggests that 1,500 to 2,000 patients must be evaluated over at least a 1-year period to determine whether the CYP2D6 genetic variation significantly alters the duration of hospital stay and costs.
authors.affiliation: Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington 40536-0082, USA.
authors.forename: W H
authors.initials: WH
authors.lastname: Chou
authors.forename: F X
authors.initials: FX
authors.lastname: Yan
authors.forename: J
authors.initials: J
authors.lastname: de Leon
authors.forename: J
authors.initials: J
authors.lastname: Barnhill
authors.forename: T
authors.initials: T
authors.lastname: Rogers
authors.forename: M
authors.initials: M
authors.lastname: Cronin
authors.forename: M
authors.initials: M
authors.lastname: Pho
authors.forename: V
authors.initials: V
authors.lastname: Xiao
authors.forename: T B
authors.initials: TB
authors.lastname: Ryder
authors.forename: W W
authors.initials: WW
authors.lastname: Liu
authors.forename: C
authors.initials: C
authors.lastname: Teiling
authors.forename: P J
authors.initials: PJ
authors.lastname: Wedlund
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics; D003362:Cost-Benefit Analysis; D019389:Cytochrome P-450 CYP2D6 / Q000172:deficiency / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007629:Kentucky; D007902:Length of Stay / Q000191:economics; D009460:Neurologic Examination / Q000187:drug effects; D010865:Pilot Projects; D011110:Polymorphism, Genetic / Q000235:genetics*; D011618:Psychotic Disorders / Q000188:drug therapy / Q000191:economics / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6